ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1398

Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal

Shuntaro Saito1, Yuko Kaneko1, Katsuya Suzuki1, Michihide Tokuhira2 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lymphocytes and methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

<Background/Purpose >

  Lymphoproliferative disorder (LPD) is a rare complication with rheumatoid arthritis (RA) patients treated with methotrexate (MTX). It is known that not little proportion of these LPD shows spontaneous regression by MTX withdrawal without chemotherapy. This study is to identify factors by which the spontaneous regression of MTX-LPD can be predicted.

<Methods >

  All 32 RA patients regarded as being complicated with MTX-LPDfrom 2007 to2013in our institution were studied. We analyzed the patients who had been observed after the withdrawal of MTX without chemotherapy. The comparisons of continuous values were examined by student t-test.

<Results >

  Five patients were given chemotherapy after the diagnosis of MTX-LPD, so we analyzed the remaining 27 patients in this study. Baseline characteristics of 27 patients were following: median age, 65 years old, female, 82%, duration of MTX administration, 7.5 years, RA duration, 11.9 years. In these patients, MTX was withdrawn without any additional treatment, and LPD was assessed during the follow up (median 5 weeks, range: 3-12 weeks). Seventeen patients were pathologically diagnosed as LPD and 10 were highly suspected of LPD with imaging tests. Spontaneous regression observed in 19 patients with 3 achieving complete remission (CR) and 16 partial remission (PR). Three patients were stable disease (SD) and 5 were progressive disease (PD).

   We focused on the time course changes in absolute number of lymphocytes at the MTX withdrawal and at the time of follow-up assessment. In CR/PR group, the number of lymphocytes were decreased at the MTX withdrawal (median 510/µL, range:87-1045), but restored at the time of follow-up assessment (median 1409/µL, 900-2969). In SD/PD group, the patients could be classified into 2 groups; 3 of low lymphocytes (median 426/µL, 255-578) and 5 of high lymphocytes (median 1725/µL, 1165-2438). However in both groups the lymphocyte counts did not change after follow up duration. Therefore, the ratio between the number of lymphocytes at the MTX withdrawal and at the time of follow-up assessment was significantly higher in PR/CR group than SD/PD group (3.73 vs 0.96, p=0.02). There was no significant difference of follow up duration between 2 groups (median 4 vs 5.5 weeks, p=0.46).

 Same tendency were observed in histologically diagnosed 17 patients. The outcomes were 2 CR, 11 PR, and 4 PD, and lymphocytes ratios were 4.07 in CR/PR group and 0.65 in SD/PD group (p=0.04).

 Of 17 histologically defined LPDs, 15 had information on Epstein Barr virus encoded small RNA (EBER). EBER positivity was relatively higher (9/11, 81%) in PR/CR group and lower (2/4,50%) in SD/PD group, but difference was not statistically significant (p=0.261).

<Conclusion >

  Careful observation of the changes in the number of lymphocytes may predict the LPD spontaneous regression after the withdrawal of MTX.

<Figure> Transition of peripheral lymphocyte counts

 


Disclosure:

S. Saito,
None;

Y. Kaneko,
None;

K. Suzuki,
None;

M. Tokuhira,
None;

T. Takeuchi,

Abbott Japan Co., Ltd., Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Sanofi–Aventis K.K., Santen Pharmaceutica,

2,

Abbott Japan Co., Ltd., Bristol–Myers K.K., Chugai Pharmaceutical Co,. Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Astellas Pharma, Diaichi Sankyo Co.,Ltd.,

8,

Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Asahi Kasei Medical K.K., Abbivie GK, Daiichi Sankyo Co.,Ltd.,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spontaneous-regression-of-methotrexate-mtx-related-lymphoproliferative-disorder-correlates-with-lymphocyte-restoration-after-mtx-withdrawal/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology